Palatin Technologies (PTNTD) AI Stock Analysis

• Market Cap: $8.76M
• Dividend Yield: N/A
• Average Volume (3M): 14.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -94.07%
• EPS Growth: 52.36%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -9.00
• Shares Outstanding: 973,341
• 10 Day Avg. Volume: 3,849
• 30 Day Avg. Volume: 14,244
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.50
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

Palatin Technologies' overall score is heavily impacted by its poor financial performance and the negative corporate event of potential delisting. While some technical indicators suggest short-term bullish momentum, the overall bearish trend and unfavorable valuation metrics underscore significant risks. The company must address its financial instability to improve its market position.

Palatin Technologies Business Overview & Revenue Model

Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

How the Company Makes Money

Palatin Technologies generates revenue through the commercialization of its pharmaceutical products, primarily Vyleesi. Revenue streams include product sales, licensing agreements, royalties, and milestone payments from strategic partnerships and collaborations with other pharmaceutical companies. The company has established partnerships for the distribution and marketing of Vyleesi in various regions, which contributes to its earnings. Additionally, Palatin may receive government grants or funding for its research and development initiatives, although these are not primary revenue sources.

Palatin Technologies Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Palatin Technologies Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTNTD, the sentiment is Neutral. The current price of 9 is above the 20-day moving average (MA) of 8.91, above the 50-day MA of 8.93, and below the 200-day MA of 26.57, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 5.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PTNTD.

Palatin Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADXN	57 Neutral	$12.79M	0.71	-162.42%	―	-82.24%	―
BOLT	52 Neutral	$9.29M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
BRTX	48 Neutral	$13.00M	―	-137.09%	―	247.62%	-7.66%
PTNTD	46 Neutral	$8.76M	―		―	-94.07%	52.36%
IBIO	42 Neutral	$15.95M	―	-101.52%	―	77.78%	84.08%
PHIO	42 Neutral	$11.80M	―	-102.18%	―	―	85.26%

Palatin Technologies Corporate Events

Palatin Technologies Stockholders Approve Key Governance Changes

On July 25, 2025, Palatin Technologies held its annual meeting of stockholders to vote on several key issues, including the election of directors and an amendment to effect a reverse stock split. The stockholders approved the election of four directors and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025. Additionally, they approved the issuance of shares upon the exercise of certain stock purchase warrants and an amendment to increase the number of shares available for equity awards. These decisions are expected to impact the company’s financial structure and governance, potentially affecting its market positioning and stakeholder interests.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Palatin Technologies Faces NYSE Delisting Proceedings

On July 7, 2025, Palatin Technologies received a notification from NYSE American LLC regarding the initiation of delisting proceedings for the company’s common stock. A hearing was held on June 18, 2025, and the decision to delist was affirmed by a Listing Qualifications Panel. Palatin Technologies plans to appeal this decision and is working to address the listing deficiencies before the full Committee for Review, expected in late August or September 2025.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Palatin Technologies Raises $340K in Private Placement

On June 10, 2025, Palatin Technologies entered into a securities purchase agreement with accredited investors to sell Series D Convertible Preferred Stock and Series I common stock purchase warrants in a private placement, closing on June 13, 2025, raising $340,000 for working capital. The Preferred Stock, convertible into common stock, and warrants were sold at $0.11 per share, with key company executives participating as purchasers. The company plans to file a registration statement for resale of shares and warrants, impacting its financial strategy and shareholder structure.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.